论文部分内容阅读
目的:观察血必净注射液治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法:将60例AECOPD患者随机分为治疗组30例、对照组30例,2组均予西医常规基础治疗,治疗组加用血必净注射液50mL加生理盐水100mL静脉滴注,1日2次,疗程均为10天。比较2组临床疗效、治疗前后炎症指标C反应蛋白(CRP)与纤维蛋白原(FIB)的改变。结果治疗组临床疗效总有效率为96.7%,对照组总有效率为80.0%,治疗组优于对照组,差异有统计学意义(P<0.05);2组治疗后CRP与FIB均较治疗前下降,治疗组更为显著,差异有统计学意义(P<0.01)。结论:血必净注射液用于辅助治疗AECOPD,有助于减轻炎症反应,提高临床疗效。
Objective: To observe the clinical efficacy of Xuebijing Injection in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Sixty patients with AECOPD were randomly divided into treatment group (n = 30) and control group (n = 30). The two groups were given conventional western medicine. The treatment group was given Xuebijing injection 50mL plus normal saline 100mL, Times, treatment are 10 days. The clinical curative effect was compared between the two groups. Changes of inflammation index C-reactive protein (CRP) and fibrinogen (FIB) before and after treatment were compared. Results The total effective rate was 96.7% in the treatment group and 80.0% in the control group, which was significantly higher in the treatment group than in the control group (P <0.05). The CRP and FIB in both groups were significantly higher than those before treatment Decline, the treatment group is more significant, the difference was statistically significant (P <0.01). Conclusion: Xuebijing Injection is a kind of adjuvant therapy for AECOPD, which helps to reduce the inflammatory reaction and improve the clinical curative effect.